StockRunway.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
New York, NY -- (SBWIRE) -- 01/30/2014 -- StockRunway.com issues special report on – Amarin Corporation plc (ADR) (NASDAQ:AMRN), Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL), CytRx Corporation (NASDAQ:CYTR), Rentech, Inc (NASDAQ:RTK)
Amarin Corporation plc (ADR) (NASDAQ:AMRN) showed a volume of 1.79 million shares by the end of last trade whereas the average volume of the stock remained 7.91 million shares. The stock opened the session at $1.78 but then moved to $1.72. At that price, the stock showed a negative performance of -2.27%. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid.
Will AMRN Get Buyers Even After The Recent Rally? Find Out Here
Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) opened the session at $4.11 and closed the session at $4.18. The stock showed a negative performance of -0.24% in previous trading session. Traded with volume of 1.76 million shares in the prior session and the average volume of the stock remained 1.33 million shares. Gol Linhas Aereas Inteligentes SA (Gol) is a Brazil-based holding company primarily engaged in the passenger air transportation sector. Through its subsidiaries, such as VRG Linhas Aereas SA, GAC Inc and Gol Finance, the Company is involved in the provision of scheduled and non-scheduled passenger air transportation services.
Has GOL Found The Bottom And Ready To Gain Momentum? Find Out Here
CytRx Corporation (NASDAQ:CYTR) opened the session at $7.06 and closed the session at $7.36. The stock showed a positive performance of 2.22% in previous trading session. Traded with volume of 1.76 million shares in the prior session and the average volume of the stock remained 4.42 million shares. The beta of the stock remained 1.33. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib.
Why Should Investors Buy CYTR After The Recent Gain? Just Go Here and Find Out
Rentech, Inc (NASDAQ:RTK) traded with volume of 1.75 million shares in the prior session and the average volume of the stock remained 2.16 million shares. The beta of the stock remained 2.40. Rentech, Inc. (Rentech) is a provider of clean energy solutions. The Company owns and operates a nitrogen fertilizer plant in East Dubuque, Illinois, that manufactures and sells natural gas-based nitrogen fertilizer products within the corn-belt region in the United States.
Is RTK a Solid Investment at These Levels? Read This Report For Details
StockRunway.com is an Elite Financial Stock website catering to individual investors, fund managers, investment bankers and equity analysts. Whether you're new to penny stocks or a seasoned veteran, you'll find all the information you will need right here! Our research is a remarkable educational tool for everyone to utilize.
Sign up TODAY and join the vast amount of investors already benefiting from the best free alerts from StockRunway's service today!
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site, Press Releases or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Read our Full Disclaimer by visiting our website.
Read Our Full Disclaimer at: http://www.stockrunway.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)